aripiprazole (Asimtufii)

Long-acting injectable antipsychotic • Brands: ABILIFY ASIMTUFII

Last reviewed: 2025-12-30

General information

Class: Long-acting injectable antipsychotic
Common US brands: ABILIFY ASIMTUFII
Long-acting injectable formulation available.
Therapeutic drug monitoring not routinely recommended; reference range 120–270 ng/mL.
Last reviewed: 2025-12-30

Dosing & forms

Forms/strengths: —
Frequency: —
Food: —
Typical range: —

Mechanism (brief)

Long-acting injectable aripiprazole formulation (D2/D3 partial agonist with 5-HT1A partial agonism and 5-HT2A antagonism) designed for every-2-month dosing for schizophrenia and bipolar I maintenance when scheduled injections support adherence.

Metabolism & Half‑life

Metabolism: CYP2D6, CYP3A4
Half‑life: Single-dose mean 504 h

Therapeutic Drug Monitoring (TDM)

Recommended: No

Reference range: 120–270 ng/mL

View labelExact

Long‑acting injectable (LAI)

Aripiprazole (Asimtufii)

Interval: Every 2 months (q8wk)
Oral overlap: Yes — 14-day oral overlap or 1-day init regimen (see label)
Site: Gluteal

Citations

Label PMCID

Monitoring highlights

Sources

ABILIFY ASIMTUFII (aripiprazole) extended-release injectable suspension — Prescribing Information — DailyMed (2025)
ABILIFY MAINTENA (aripiprazole) extended-release injectable suspension — Prescribing Information — DailyMed (2025)
The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia — American Psychiatric Association (2020)
CANMAT and ISBD Guidelines for the Management of Patients With Bipolar Disorder: 2021 Update — Bipolar Disorders (2021)
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 — Pharmacopsychiatry (2018)